←Back to Expert Scholars
Translational Medicine / 转化医学DNA Methylation, Oral CC-486
Eric Diehl
MD
🏢Bristol Myers Squibb🌐USA
Senior Director, Clinical Development
25
h-index
0
Key Papers
0
Key Contributions
👥Biography 个人简介
Eric Diehl has led clinical development of oral azacitidine (CC-486) for AML maintenance therapy following the QUAZAR trial. His work bridges industry development and academic trial networks. He coordinates regulatory interactions for hypomethylating programs.
Share:
🧪Research Fields 研究领域
CC-486
oral azacitidine
AML maintenance
clinical development
hypomethylating agents
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Melanoma ImmunotherapyCheckpoint Inhibitors
Drew M. Pardoll
Johns Hopkins University
Cancer ImmunologyPD-1/PD-L1 Pathway
Padmanee Sharma
MD Anderson Cancer Center
Bladder Cancer ImmunotherapyImmune Profiling
Naiyer A. Rizvi
Columbia University Irving Medical Center
Lung Cancer ImmunotherapyTumor Mutational Burden
关注 Eric Diehl 的研究动态
Follow Eric Diehl's research updates
留下邮箱，当我们发布与 Eric Diehl（Bristol Myers Squibb）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment